BRS4-FM3-PM7 - Ketone Utilisation Capacity
(Using Ketones to Sustain Cellular Energy When Glucose Availability Changes)
1. Mission & Overview
Mission
Enable mitochondrial ketone utilisation so alternative fuel is available when glucose conditions shift.
Overview
Supports capacity to transport, metabolise, and utilise ketone bodies (beta-hydroxybutyrate and acetoacetate, alternative fuels the liver produces when glucose availability falls) as mitochondrial energy substrates when glucose conditions change. This pathway provides metabolic fuel flexibility distinct from the carbohydrate- or fat-transport routes covered elsewhere, becoming physiologically relevant during fasting, prolonged exercise, or carbohydrate-restricted eating patterns. Mitochondrial ketone-oxidation enzyme capacity, not just circulating ketone levels, determines how effectively this alternative fuel is actually used.
- Metabolises ketone bodies as alternative mitochondrial fuel.
- Becomes relevant during fasting, exercise, or carbohydrate restriction.
- Depends on ketone-oxidation enzyme capacity, not just circulating ketone levels.
2. Primary Biological Effects
↑ ketone utilisation; ↑ alternative fuel capacity; ↑ energetic resilience under changing substrate availability
3. Phenome Connections
These mappings are translational relationships, not single-mechanism outcome claims. Phenomes are emergent functional patterns supported by multiple interacting PMs across the BRAIN Framework. Biology → Phenome Confidence reflects how directly this mechanism's biology would be expected to affect the phenome within BRAIN architecture — not dietary treatment efficacy. Evidence Confidence (below Key References) reflects how convincing the attached evidence is for the Biology → Phenome relationship on that row.
These are three independent scores. They are not combined or averaged. A phenome can have Medium registry evidence while individual mechanism rows show different Biology → Phenome and Evidence scores.
1. Phenome Evidence Confidence (Phenome Registry only)
Question: How convincing is the foundational evidence that this phenome is a valid, well-defined functional construct — and that diet-relevant biology can plausibly connect to it?
Not a roll-up of Biology → Phenome Confidence or Evidence Confidence from Primary Mechanism page rows. Those are scored per mechanism; this score is assigned once per phenome at registry level.
Derived from foundational landmark evidence organised in up to three layers: construct validation, biology→phenome linkage, and nutrition→biology modulation. Each layer may include one or many landmark papers depending on registry review.
2. Biology → Phenome Confidence (Primary Mechanism page §3 rows)
Question: If this PM/FM biology were substantially impaired in isolation, how directly would that phenome be expected to suffer — within BRAIN architecture?
How it is derived: Reviewers read the PM/FM definition and biological function first — initially ignoring attached references and whether dietary intervention studies exist. References are reviewed only when scoring Evidence Confidence (below).
Score levels (the value shown on each row as Biology → Phenome Confidence):
- High — primary biological determinant (e.g. noradrenergic signalling → attention; GABA synthesis → calming tone)
- Medium — major contributory determinant, not the sole driver
- Low–Medium — established but indirect, modulatory, or one integrative step removed
- Low — distal, conditional, or weak biological coupling
“Not dietary treatment efficacy” means this score does not ask whether a diet or supplement treats the phenome. It asks whether the biology itself is architecturally relevant. Limited dietary RCT evidence belongs in Evidence Confidence, not here.
3. Evidence Confidence (Primary Mechanism page §3 rows)
Question: How convincing are the attached Key References on that specific row that this biology actually relates to this phenome?
How it is derived: Assigned after Biology → Phenome Confidence, by reviewing only the references on that PM/FM row. Judges whether refs support the relationship — not just mechanism or phenome in isolation.
- High — strong convergent human evidence directly linking mechanism biology to phenome variation
- Medium — multiple human lines supporting the relationship; may include one bridge study with an inferential step
- Low–Medium — convergent translational stack without direct mechanism↔phenome measurement on the row
- Low — mechanistic or preclinical only; mechanism and phenome supported separately but not bridged
Often equal to or lower than Biology → Phenome Confidence. Can occasionally be higher when outcome evidence is stronger than the mechanism's contributory role.
- Biology → Phenome Confidence: Low
- Rationale: ADHD mitochondrial dysfunction reviews describe substrate-flexibility strain when oxidative phosphorylation is impaired — ketone utilisation is an indirect alternative-fuel pathway node without ADHD ketone-intervention outcomes in the hub set.
- Key References:
- Evidence Confidence: Low
- Biology → Phenome Confidence: Low
- Rationale: Capacity to oxidise ketone bodies may contribute to metabolic adaptability when glucose/fat routing is constrained — framework translation from ADHD bioenergetic reviews rather than direct resilience-outcome measurement.
- Key References:
- Evidence Confidence: Low
4. Levers
Intervention Profile
Intervention Dominance: Diet/Lifestyle-Combined
- Lower-carbohydrate whole-food patterns ← vegetables, protein-rich meals, nuts, legumes when metabolic context supports ketone production
- Mixed macronutrient whole-food meals ← broader substrate-flexibility context
- Adequate protein intake ← amino-acid substrate support within varied fuel patterns
- None listed
-
Amino acids ← fish, eggs, dairy, legumes
-
Fatty acids ← fish, eggs, olive oil, nuts, seeds
-
Glucose ← oats, barley, legumes, fruit
1. Food Preparation & Delivery ONLY
- Avoid persistent energy surplus and maintain varied whole-food meals that support switching between glucose, fatty-acid, and ketone utilisation rather than fixed high-glycaemic loading (Evidence:Human Mechanistic) [Fuehrlein et al., 2004]
- Use complementary protein pairing and distributed protein across meals to support amino-acid availability — see Lentils — Synergies, Chickpeas — Synergies.
- Prepare cruciferous vegetables to support myrosinase-dependent sulforaphane yield — see Broccoli Sprouts — Preparation.
- Include regular aerobic and mixed-intensity activity to raise metabolic demand and support mitochondrial capacity for alternative fuel oxidation (Evidence:Human Mechanistic) [de Guia et al., 2019]
5. Mechanistic Basis
Summary
Ketone bodies provide an alternative energy substrate that can be oxidised within mitochondria to generate ATP. During periods of reduced glucose availability, ketones can contribute meaningfully to whole-body and brain energy metabolism [Ramezani et al., 2023; López-Ojeda et al., 2023].
(Hepatic production and peripheral oxidation)
Ketones are produced primarily by the liver and transported to peripheral tissues—including the brain via monocarboxylate transporters—where they enter mitochondrial energy pathways and support ATP production [López-Ojeda et al., 2023; Ramezani et al., 2023].
(Metabolic flexibility context)
Within BRS4(FM3), ketone utilisation contributes to substrate flexibility by supporting energy production across varying nutritional and physiological conditions. The mechanism should not be interpreted as advocating ketogenic diets universally but rather as describing an underlying metabolic capability [López-Ojeda et al., 2023; Ramezani et al., 2023].
(Boundaries of the mechanism)
This PM addresses ketone transport and mitochondrial utilisation — not long-chain fatty-acid import (BRS4-FM3-PM6 - Carnitine-Mediated Fat Transport), electron transport chain function (BRS4-FM1-PM1 - Electron Transport Chain Function), or NAD⁺ redox economy (BRS4-FM1-PM2 - NAD⁺ Metabolism).
5.1 Evidence Highlights
Introduction/Summary
Ketone utilisation as an alternative brain fuel is mechanistically established. The findings below emphasise brain energetic substrate biology.
- Confidence: low-medium
- Evidence Level: mechanistic
- Rationale: Ketone bodies can be transported to the brain and oxidised within mitochondria to support ATP production during reduced glucose availability [Ramezani et al., 2023; López-Ojeda et al., 2023]. This establishes ketone utilisation as a legitimate alternative fuel pathway within substrate flexibility — not a universal dietary prescription.
- Key References:
6. BRS Pathways and Connections
6.1 BRS Pathways
- None listed
6.2 Cross-BRS Mechanism Relationships
Primary Mechanisms in other Biological Regulatory Systems that directly interact with, constrain or support this mechanism.
- BRS6-FM1-PM2 - Glycaemic Variability Regulation — biological connection relevant to this mechanism
6.3 Local BRS Mechanism Relationships
Related Primary Mechanisms within the same Biological Regulatory System that collectively support the integrated biological function.
7. Scoreable Inputs & Modulation Signals
This PM is scoreable through macronutrient-pattern and metabolic-exposure signals relevant to ketone production and utilisation capacity.
| Input Category | Example Inputs | PM7 Relevance |
|---|---|---|
| Functional Property Potentials | carbohydrate_load_pattern; mixed_substrate_meal_density; fasting_window_exposure | May reflect contexts that engage ketone pathways. |
| Realised Functional States | lower_carb_whole_food_pattern; post_exercise_fuel_shift | Reflect practical ketone-utilisation contexts. |
| Preparation Transformations | minimally_processed; whole_food_matrix | May preserve substrate-quality context for metabolic flexibility. |
8. References
- Ramezani et al. (2023) — Ketone Bodies and Brain Energy Metabolism
- López-Ojeda et al. (2023) — New Insights and Perspectives for Neurological Diseases
- Fuehrlein et al. (2004) — Ketogenic Diet Metabolic Effects
- de Guia et al. (2019) — Exercise and Skeletal Muscle NAD⁺ Salvage
- Omori et al. (2024) — Exogenous Ketones and Ketogenic Diet in Clinical Contexts
- van Oudheusden and Scholte (2002) — Efficacy of Carnitine in the Treatment of Children with Attention-deficit Hyperactivity Disorder
- Öğütlü et al. (2022) — Mitochondrial Dysfunction in Attention Deficit Hyperactivity Disorder